RSV vaccines and Guillain-Barré syndrome: Insights into an emerging concern

Area of Science:

• Immunology
• Neurology
• Public Health

Background:

• Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections, particularly in infants and the elderly.
• Recent approval of multiple RSV vaccines offers a significant public health advancement.
• Post-marketing surveillance has indicated a potential increase in Guillain-Barré syndrome (GBS) following RSV vaccination.

Purpose of the Study:

• To explore potential associations between RSV vaccination and Guillain-Barré syndrome (GBS).
• To consider alternative mechanisms, such as electrolyte imbalances, linking GBS and RSV vaccination.
• To emphasize the importance of ongoing safety monitoring for new vaccines.

Main Methods:

• Review of post-marketing surveillance data for RSV vaccine adverse events.
• Analysis of proposed pathomechanisms for GBS, including molecular mimicry, host genetics, and electrolyte disorders like SIADH-induced hyponatremia.
• Consideration of epidemiological overlap between GBS incidence and the primary RSV vaccine target population (>65 years).

Main Results:

• RSV vaccination is associated with an increased incidence of Guillain-Barré syndrome (GBS).
• Electrolytic disorders, specifically SIADH-induced hyponatremia, are proposed as a potential contributing factor to GBS.
• The demographic overlap between GBS and the elderly RSV vaccine recipients requires careful attention.

Conclusions:

• While RSV vaccines provide substantial benefits, their association with GBS necessitates continued safety surveillance.
• Investigating rare adverse events like GBS is crucial for maintaining public trust and maximizing vaccine benefits.
• Understanding the mechanisms behind GBS post-vaccination is essential for risk mitigation.